@FierceBiotech: Gates' legendary discipline transforms vaccine effort. Item | Follow @FierceBiotech
@JohnCFierce: Inhibitex shares have more than doubled since their release discussing their interferon-free approach to hep C. Story | Follow @JohnCFierce
@RyanMFierce: Looks like Pfizer won't be axing as many R&D workers at Sandwich UK site as we thought. Retaining 650 workers. News | Follow @RyanMFierce
> Dynavax Technologies ($DVAX), a developer of a vaccine against hepatitis B, said it plans to raise $60 million in a stock sale. Report
> Galena Biopharma ($GALE) reported "positive" data today from mid-stage trials of its therapeutic vaccine called NeuVax for the treatment of breast cancer. The company said patients on its vaccine had a 48% reduced risk of cancer recurrence compared with the control group. Release
> Rexahn Pharmaceuticals' ($RNN) shares tanked on news that its Phase IIb study of Serdaxin for major depression didn't show efficacy compared with placebo. Item
> The New York Genome Center said it is set to open early next year, spending $125 million to establish one of the biggest genomic research hubs in the world. Report
Pharma News
@FiercePharma: GSK settles U.S. investigation for $3B. News | Follow @FiercePharma
> FDA panel approves outcomes claim for Vytorin. Item
> New Medicare code could boost Krystexxa sales. Story
> Off-label doses of Medtronic bone product risky, study shows. More
> Report: Teva, Ranbaxy team up to launch U.S. Lipitor copy. Article
> Is the U.K.'s cancer-drugs fund unfair? Piece
> Co-pay cards to hike drug costs $32B, report says. Article
And Finally... Brain scans show that fatty foods and sugary drinks can be addictive like narcotics. Article